| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | group | BEFREE | The expanded NK cells exhibit increased cytotoxic function against a panel of blood cancer and solid tumor cells as compared to IL-2-activated non-expanded NK cells. | 31624330 | 2019 | ||||
|
0.080 | Biomarker | group | BEFREE | Moreover, progress has been achieved in targeting the IL-2 receptor to treat autoimmune diseases, organ transplantation and certain hematological malignancies. | 29055191 | 2017 | ||||
|
0.080 | Biomarker | group | BEFREE | A novel biopharmaceutical, consisting of the F8 mAb (specific to a splice isoform of fibronectin) simultaneously fused to both TNF and IL2, was found to react with the majority of solid tumors and hematologic malignancies in mouse and man, but not with healthy adult tissues. | 28716814 | 2017 | ||||
|
0.080 | AlteredExpression | group | BEFREE | Overexpression of interleukin 2 receptor (IL2R) in hematological malignancies has been utilized to target leukemia. | 26984209 | 2016 | ||||
|
0.080 | AlteredExpression | group | BEFREE | One agent, containing human interleukin-2 and truncated diphtheria toxin (denileukin diftitox), has been approved for use in cutaneous T-cell lymphoma, and has shown activity in other hematologic malignancies, including leukemias and lymphomas. | 19344187 | 2009 | ||||
|
0.080 | Biomarker | group | LHGDN | In vitro IL-2 incubation induces CD69 expression and other phenotypic changes on NK subpopulations present in PBPC collections. | 15539078 | 2004 | ||||
|
0.080 | Biomarker | group | BEFREE | The aim of this study was to evaluate the occurrence of T-cell spontaneous apoptosis (A(spont)) and its modulation in vitro by the interleukin-2 receptor (IL-2R) gamma-chain (gammac)-signaling cytokine IL-15 in patients transplanted with autologous peripheral blood progenitor cells (PBPC) for hematologic malignancies. | 11750110 | 2001 | ||||
|
0.080 | Biomarker | group | BEFREE | These studies suggest that IL-2-activated UCBCs may be a useful source of cellular therapy for patients with hematological malignancies and breast cancer. | 11106253 | 2000 |